GGrantIndex
← Leaderboards

Kenneth S Kosik

University Of California Santa Barbara

Google Scholar ↗PubMed ↗ORCID ↗
$22,120,158
Attributed
$27,079,161
Total exposure
18
Grants
10
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $3.4M · FY2005–25
$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$27,079,161 · 18

By mechanism

R01$12,732,144 · 7
U01$6,224,321 · 2
RF1$2,591,132 · 1
U54$1,535,811 · 1
R21$1,109,752 · 3
P50$1,085,282 · 1

Top collaborators

Most similar at University Of California Santa Barbara

Same institution · by research overlap

Others in their field

Top investigators on “Alzheimer&Apos”

Research focus

Alzheimer&AposTau ProteinsNeuronsS DiseaseCellsPathologyDesignNeurofibrillary TanglesPathway InteractionsIn VitroPhenotypePathologicBaseTau MutationLeadBindingDetectionLinkTau AggregationTauopathiesProgramsPharmaceutical PreparationsAntibodiesInvestigation

Grant awards (62)

Preventing Tau uptake by novel inhibitors of tau binding to LRP1$786,735
R01 · FY2025 · AG · contact PI
Drivers of Pathological Tau Aggregation$659,979
R01 · FY2025 · AG · contact PI
Preventing Tau uptake by novel inhibitors of tau binding to LRP1$809,235
R01 · FY2024 · AG · contact PI
Drivers of Pathological Tau Aggregation$711,751
R01 · FY2024 · AG · contact PI
The complex interaction between Alzheimer drivers and aging$619,969
R01 · FY2024 · AG · contact PI
Preventing Tau uptake by novel inhibitors of tau binding to LRP1$853,145
R01 · FY2023 · AG · contact PI
Drivers of Pathological Tau Aggregation$711,751
R01 · FY2023 · AG
Preventing Tau uptake by novel inhibitors of tau binding to LRP1$885,722
R01 · FY2022 · AG · contact PI
Drivers of Pathological Tau Aggregation$711,751
R01 · FY2022 · AG
A novel approach to restricting the spread of neurofibrillary tau$348,075
R41 · FY2022 · AG
A novel approach to restricting the spread of neurofibrillary tau$110,250
R41 · FY2022 · AG
A novel approach to restricting the spread of neurofibrillary tau$36,750
R41 · FY2022 · AG
Molecular Basis of the Tau Aggregation Pathway$529,479
R01 · FY2021 · AG
A novel approach to restricting the spread of neurofibrillary tau$349,580
R41 · FY2021 · AG
The complex interaction between Alzheimer drivers and aging$2,591,132
RF1 · FY2020 · AG · contact PI
Molecular Basis of the Tau Aggregation Pathway$529,479
R01 · FY2020 · AG
Project 2: Tau uptake mechanisms and neuronal excitability in FTD$296,067
U54 · FY2020 · NS · contact PI
The complex interaction between Alzheimer drivers and aging$732,363
R56 · FY2019 · AG · contact PI
Molecular Basis of the Tau Aggregation Pathway$529,479
R01 · FY2019 · AG
Project 2: Tau uptake mechanisms and neuronal excitability in FTD$296,063
U54 · FY2019 · NS · contact PI
Molecular Basis of the Tau Aggregation Pathway$529,479
R01 · FY2018 · AG
Project 2: Tau uptake mechanisms and neuronal excitability in FTD$310,408
U54 · FY2018 · NS · contact PI
Molecular Basis of the Tau Aggregation Pathway$295,888
R01 · FY2018 · AG
Development of Cdk5 Inhibitors$657,821
U01 · FY2017 · AG · contact PI
Molecular Basis of the Tau Aggregation Pathway$529,479
R01 · FY2017 · AG
Project 2: Tau uptake mechanisms and neuronal excitability in FTD$321,629
U54 · FY2017 · NS · contact PI
Project 2: Tau uptake mechanisms and neuronal excitability in FTD$311,644
U54 · FY2016 · NS · contact PI
Development of Cdk5 Inhibitors$1,294,544
U01 · FY2011 · AG · contact PI
Development of RNAi as Treatment for Neurodegeneration$126,758
R01 · FY2011 · AG · contact PI
Development of Cdk5 Inhibitors$1,229,542
U01 · FY2010 · AG · contact PI
Development of RNAi as Treatment for Neurodegeneration$131,891
R01 · FY2010 · AG · contact PI
Development of Cdk5 Inhibitors$1,090,050
U01 · FY2009 · AG · contact PI
Development of RNAi as Treatment for Neurodegeneration$133,767
R01 · FY2009 · AG · contact PI
Development of RNAi as Treatment for Neurodegeneration$133,781
R01 · FY2008 · AG · contact PI
Development of Cdk5 Inhibitors$951,096
U01 · FY2007 · NS · contact PI
Tau Degradation Pathways$203,499
R01 · FY2007 · AG · contact PI
Development of RNAi as Treatment for Neurodegeneration$147,321
R01 · FY2007 · AG · contact PI
Development of Cdk5 Inhibitors$1,001,268
U01 · FY2006 · NS · contact PI
Tau Degradation Pathways$209,576
R01 · FY2006 · AG · contact PI
Tau Degradation Pathways$212,580
R01 · FY2005 · AG
Development of RNAi as Treatment for Neurodegeneration$132,300
R21 · FY2005 · AG
Tau Degradation Pathways$40,000
R01 · FY2005 · AG
Tau Degradation Pathways$252,580
R01 · FY2004 · AG
The Regulation of Neuronal miRNA Expression$205,438
R21 · FY2004 · NS
Compound Identification in Assays for Tau Pathology$205,438
R21 · FY2004 · NS
Development of RNAi as Treatment for Neurodegeneration$155,700
R21 · FY2004 · AG
FUNCTIONS AND INTERACTIONS OF PRESENILINS$298,838
R01 · FY2003 · AG
The Regulation of Neuronal miRNA Expression$205,438
R21 · FY2003 · NS
Compound Identification in Assays for Tau Pathology$205,438
R21 · FY2003 · NS
FUNCTIONS AND INTERACTIONS OF PRESENILINS$291,688
R01 · FY2002 · AG
SIGNALING IN PRESENILINS$0
P01 · FY2002 · AG
Cell biology of alpha synuclein &parkin and dynamic cellular models$0
P50 · FY2002 · NS
FUNCTIONS AND INTERACTIONS OF PRESENILINS$284,076
R01 · FY2001 · AG
Cell biology of alpha synuclein &parkin and dynamic cellular models$248,088
P50 · FY2001 · NS
Cell biology of alpha synuclein &parkin and dynamic cellular models$0
P50 · FY2001 · NS
SIGNALING IN PRESENILINS$0
P01 · FY2001 · AG
NEURONAL POLARITY$296,668
R01 · FY2000 · NS
Cell biology of alpha synuclein &parkin and dynamic cellular models$294,553
P50 · FY2000 · NS
Cell biology of alpha synuclein &parkin and dynamic cellular models$294,553
P50 · FY2000 · NS
FUNCTIONS AND INTERACTIONS OF PRESENILINS$275,800
R01 · FY2000 · AG
Cell biology of alpha synuclein &parkin and dynamic cellular models$248,088
P50 · FY2000 · NS
SIGNALING IN PRESENILINS$223,701
P01 · FY2000 · AG